Preclinical Evaluation of a Regimen Combining Chidamide and ABT-199 in Acute Myeloid Leukemia

By
Justin.choi
-
0
16
Scientists reported that a newly emerged histone deacetylase inhibitor, chidamide, at low-cytotoxicity dose enhanced the anti-AML activity of ABT-199, while sparing normal hematopoietic progenitor cells.
[Cell Death & Disease]
Chen, K., Yang, Q., Zha, J., Deng, M., Zhou, Y., Fu, G., Bi, S., Feng, L., Xu-Monette, Z. Y., Chen, X. L., Fu, G., Dai, Y., Young, K. H., & Xu, B. (2020). Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia. Cell Death & Disease, 11(9), 1–13. https://doi.org/10.1038/s41419-020-02972-2 Cite
Full Article